Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TENX | US
0.33
2.36%
Healthcare
Biotechnology
30/06/2024
24/04/2026
14.30
14.09
14.50
13.67
Tenax Therapeutics Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV) TNX-102 and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib) a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics Inc. and changed its name to Tenax Therapeutics Inc. in September 2014. Tenax Therapeutics Inc. was founded in 1967 and is based in Chapel Hill North Carolina.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
57.7%1 month
77.4%3 months
91.7%6 months
88.4%-
0.30
1.50
0.03
0.03
-0.14
-
-
-13.03M
48.75M
48.75M
-
-
-
-
-113.79
0.95
1.13
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.94
Range1M
3.84
Range3M
6.58
Rel. volume
0.77
Price X volume
5.22M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| LYRA THERAPEUTICS INC | LYRA | Biotechnology | 0.8 | 52.37M | 10.34% | n/a | 118.63% |
| 22nd Century Group Inc | XXII | Biotechnology | 1.66 | 52.18M | -2.92% | n/a | -1072.15% |
| Cognition Therapeutics Inc. Common Stock | CGTX | Biotechnology | 1.28 | 51.37M | 1.59% | n/a | 2.71% |
| Gain Therapeutics Inc. Common Stock | GANX | Biotechnology | 1.97 | 50.30M | 4.23% | n/a | 6.85% |
| PEPG | PEPG | Biotechnology | 1.54 | 50.19M | -3.14% | n/a | 12.52% |
| Clene Nanomedicine Inc | CLNN | Biotechnology | 5.91 | 47.06M | -3.90% | n/a | -6472.02% |
| Minerva Neurosciences Inc | NERV | Biotechnology | 6.575 | 45.98M | -3.73% | n/a | -194.60% |
| TPST | TPST | Biotechnology | 1.79 | 45.12M | -0.56% | n/a | 119.58% |
| Enveric Biosciences Inc | ENVB | Biotechnology | 5.04 | 44.96M | 25.37% | n/a | 0.00% |
| Mereo BioPharma Group plc | MREO | Biotechnology | 0.29 | 44.62M | -5.41% | n/a | 7.83% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 21.77 | 33.16M | -2.81% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.14 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.50 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 91.68 | 72.80 | Riskier |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.03 | 0.25 | Cheaper |
| Market Cap | 48.75M | 3.66B | Emerging |